Literature DB >> 6355542

Aspirin-sulfinpyrazone in prophylaxis of deep venous thrombosis in total hip replacement.

R D Sautter, E L Koch, W O Myers, J R Ray, J J Mazza, D E Larson, H M Chen, J P Milbauer, P S Treuhaft, E D Plotka.   

Abstract

In postoperative hip arthroplasty patients, treatment with aspirin and sulfinpyrazone resulted in a statistically significant reduction of venographically diagnosed thrombi in the proximal veins of the leg. This reduction was most apparent in thrombi that involved the iliac vein. When compared with their placebo-treated counterparts, female patients who received the active treatment experienced a statistically significant 75% reduction of thrombosis, compared with a 32% reduction for men that was not statistically significant. There were no serious adverse effects. Factors were identified that may influence the result of drug prophylaxis trials in deep-vein thrombosis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6355542

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  4 in total

1.  Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Yngve Falck-Ytter; Charles W Francis; Norman A Johanson; Catherine Curley; Ola E Dahl; Sam Schulman; Thomas L Ortel; Stephen G Pauker; Clifford W Colwell
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Collaborative overview of randomised trials of antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-22

Review 3.  Aspirin in cardiovascular disease.

Authors:  I A Reilly; G A FitzGerald
Journal:  Drugs       Date:  1988-02       Impact factor: 9.546

Review 4.  Prevention of VTE in patients having major orthopedic surgery.

Authors:  Charles W Francis
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.